Udenafil

Synonym(s):3-(1-Methyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide;3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-propoxybenzenesulfonamide;3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-propoxybenzenesulfonamide;5-[2-Propoxy-5-(1-methyl-2-pyrrolidinylethyl amidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one;5-[2-Propyloxy-5-(1-methyl-2-pyrrolidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one

CAS NO.：268203-93-6
Empirical Formula: C25H36N6O4S
Molecular Weight: 516.66
MDL number: MFCD20275557
EINECS: 251-228-4
SAFETY DATA SHEET (SDS)
Update Date: 2023-09-11 16:43:46

What is Udenafil?

Description

Udenafil is the fourth in a class of drugs targeting the inhibition of the enzyme phosphodiesterase 5 (PDE5) for the treatment of erectile dysfunction. Inhibition of PDE5 results in the increase in endogenous cyclic guanosine monophosphate (cGMP) concentrations in the penile corpus cavernosum. cGMP induces smooth muscle cell relaxation and subsequent increased blood flow leading to a sustainable erection. Udenafil is a potent antagonist of human PDE5 with an IC₅₀ of 8.25nM and a comparable selectivity profile as sildenafil for the other PDEs. Unlike tadalafil, it does not inhibit PDE11, which has been implicated in myalgia and testicular toxicity. Furthermore, udenafil produced up to a 91% vaginal penetration success rate and up to a 67% intercourse completion rate compared to a 29% completion rate by placebo. Overall patient satisfaction, measured by a standard global assessment question, was 86% compared to only 26% in the placebo group. The most frequently recorded adverse events were mild-to-moderate facial flushing and headache.

The Uses of Udenafil

Udenafil is an oral phosphodiesterase 5 inhibitor used for the treatment of erectile dysfunction.

What are the applications of Application

Udenafil is an oral PDE5A (phosphodiesterase 5) inhibitor.

Background

Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena. It is not yet approved for use in the U.S., E.U., or Canada.

Indications

Investigated for use/treatment in erectile dysfunction and hypertension.

Pharmacokinetics

Udenafil is a potent selective phosphodiesterase type 5 (PDE5) inhibitor.

Metabolism

Hepatic. Metabolized by CYP3A4 and CYP3A5.

Properties of Udenafil

Melting point:	152-159°C
Boiling point:	697.0±65.0 °C(Predicted)
Density	1.35
storage temp.	under inert gas (nitrogen or Argon) at 2-8°C
solubility	Chloroform (Slightly), Methanol (Sparingly)
form	Solid
color	White to Pale Beige